Acticor Biotech SAS (ALACT.PA)
5.58 €
-0.08 (-1.41%)
Rating:
Recommendation:
-
| Symbol | ALACT.PA |
|---|---|
| Price | 5.58 € |
| Beta | 0.000 |
| Volume Avg. | 0.00M |
| Market Cap | 68.643M |
| Shares () | - |
| 52 Week Range | 5.1-11.0 |
| 1y Target Est | - |
| DCF Unlevered | ALACT.PA DCF -> | |
|---|---|---|
| DCF Levered | ALACT.PA LDCF -> | |
| ROE | - | |
| ROA | - | |
| Operating Margin | - | |
| Debt / Equity | 162.61% | Buy |
| P/E | -3.72 | Strong Sell |
| P/B | 13.58 | Strong Buy |
About
Download (Excel)Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.